Item 16. Form 10-K Summary.
4K characters. Original on sec.gov · Markdown
Item 16. Form 10-K Summary.
None.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| CVS HEALTH CORPORATION | |||||||||||
| Date: | February 8, 2023 | By: | /s/ SHAWN M. GUERTIN | ||||||||
| Shawn M. Guertin | |||||||||||
| Executive Vice President and Chief Financial Officer |
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title(s) | Date | ||||||||||||
| /s/ FERNANDO AGUIRRE | Director | February 8, 2023 | ||||||||||||
| Fernando Aguirre | ||||||||||||||
| /s/ JEFFREY R. BALSER, M.D., Ph.D. | Director | February 8, 2023 | ||||||||||||
| Jeffrey R. Balser, M.D., Ph.D. | ||||||||||||||
| /s/ C. DAVID BROWN II | Director | February 8, 2023 | ||||||||||||
| C. David Brown II | ||||||||||||||
| /s/ JAMES D. CLARK | Senior Vice President - Controller and Chief | February 8, 2023 | ||||||||||||
| James D. Clark | Accounting Officer (Principal Accounting Officer) | |||||||||||||
| /s/ ALECIA A. DECOUDREAUX | Director | February 8, 2023 | ||||||||||||
| Alecia A. DeCoudreaux | ||||||||||||||
| /s/ NANCY-ANN M. DEPARLE | Director | February 8, 2023 | ||||||||||||
| Nancy-Ann M. DeParle | ||||||||||||||
| /s/ ROGER N. FARAH | Chair of the Board and Director | February 8, 2023 | ||||||||||||
| Roger N. Farah | ||||||||||||||
| /s/ ANNE M. FINUCANE | Director | February 8, 2023 | ||||||||||||
| Anne M. Finucane | ||||||||||||||
| /s/ SHAWN M. GUERTIN | Executive Vice President and Chief Financial | February 8, 2023 | ||||||||||||
| Shawn M. Guertin | Officer (Principal Financial Officer) | |||||||||||||
| /s/ EDWARD J. LUDWIG | Director | February 8, 2023 | ||||||||||||
| Edward J. Ludwig | ||||||||||||||
| /s/ KAREN S. LYNCH | President and Chief Executive Officer | February 8, 2023 | ||||||||||||
| Karen S. Lynch | (Principal Executive Officer) and Director | |||||||||||||
| /s/ JEAN-PIERRE MILLON | Director | February 8, 2023 | ||||||||||||
| Jean-Pierre Millon | ||||||||||||||
| /s/ MARY L. SCHAPIRO | Director | February 8, 2023 | ||||||||||||
| Mary L. Schapiro | ||||||||||||||
| /s/ WILLIAM C. WELDON | Director | February 8, 2023 | ||||||||||||
| William C. Weldon |
Previous: Item 15. Exhibits, Financial Statement Schedules.
Sponsor Sponsor this sector. One slot per industry, shown on every filing in it. Details